Placebo + Mesalamine + Mesalamine

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Mild to Moderate Ulcerative Colitis

Conditions

Mild to Moderate Ulcerative Colitis

Trial Timeline

Jan 1, 2008 → Aug 1, 2009

NCT ID

NCT01045018

About Placebo + Mesalamine + Mesalamine

Placebo + Mesalamine + Mesalamine is a phase 3 stage product being developed by Eagle Pharmaceuticals for Mild to Moderate Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01045018. Target conditions include Mild to Moderate Ulcerative Colitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01045018	Phase 3	Completed	Jan 1, 2008	Aug 1, 2009	Mild to Moderate Ulcerative Colitis

Competing Products

20 competing products in Mild to Moderate Ulcerative Colitis

See all competitors

Product	Company	Stage	Hype Score
Neurosteroid enantiomer	Oragenics	Phase 2	44
Ranirestat + Placebo	Eisai	Phase 2/3	65
Aricept (donepezil hydrochloride) + placebo	Eisai	Approved	85
Donepezil HCl	Eisai	Approved	85
Donanemab + Aducanumab	Eli Lilly	Phase 3	77
PPAR alpha + Hydrochlorothiazide + Placebo	Eli Lilly	Phase 2	52
Elagolix	AbbVie	Approved	85
AZD1446 + Placebo	AstraZeneca	Phase 2	52
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection	AstraZeneca	Phase 1	33
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg	AstraZeneca	Approved	85
AZD5213 + AZD5213 + AZD5213	AstraZeneca	Phase 2	52
budesonide/formoterol (Symbicort)	AstraZeneca	Phase 3	77
MK-8931	Merck	Phase 1	33
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	23
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)	Merck	Phase 3	77
Aliskiren + Hydrochlorothiazide + Amlodipine	Novartis	Approved	85
LCZ696 + Sildenafil	Novartis	Phase 2	52
QCZ484 + Placebo	Novartis	Phase 1	33
Rivastigmine Patch	Novartis	Approved	85
AFQ056	Novartis	Phase 1	33

Other Products from Eagle Pharmaceuticals

Arm 1 Cataract Surgery performed with remimazolam as sedative + Arm 2 Cataract Surgery performed with standard of care sedativeApproved

Ryanodex and Standard of CarePhase 3

CAL02 + PlaceboPhase 2

Ryanodex (dantrolene sodium) for injectable suspensionPhase 2

Dantrolene sodium for injectable suspensionPhase 2